{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+%28Renal+Cell%29+Cancer&page=43", "query": { "condition": "Kidney (Renal Cell) Cancer", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 1535, "total_pages": 154, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+%28Renal+Cell%29+Cancer&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+%28Renal+Cell%29+Cancer&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T01:12:54.931Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00672178", "title": "Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Stereotactic body radiation", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1, "start_date": "2008-03", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2017-01-12", "last_synced_at": "2026-10-20T01:12:54.931Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00672178" }, { "nct_id": "NCT00389285", "title": "Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "rIL-21 only", "type": "DRUG" }, { "name": "rIL-21 + sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ZymoGenetics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2006-10", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2009-05-27", "last_synced_at": "2026-10-20T01:12:54.931Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Lebanon, New Hampshire", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00389285" }, { "nct_id": "NCT04940299", "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Bladder Carcinoma", "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Renal Pelvis Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Malignant Solid Neoplasm", "Metastatic Bladder Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Melanoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Lung Cancer AJCC v6", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-09-23", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-20T01:12:54.931Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04940299" }, { "nct_id": "NCT01155258", "title": "Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer", "Hereditary Paraganglioma", "Male Breast Cancer", "Malignant Paraganglioma", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Pheochromocytoma", "Pancreatic Polypeptide Tumor", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Neuroendocrine Carcinoma of the Skin", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pheochromocytoma", "Recurrent Prostate Cancer", "Recurrent Renal Cell Cancer", "Recurrent Small Cell Lung Cancer", "Recurrent Uterine Sarcoma", "Regional Gastrointestinal Carcinoid Tumor", "Regional Pheochromocytoma", "Stage III Cervical Cancer", "Stage III Endometrial Carcinoma", "Stage III Neuroendocrine Carcinoma of the Skin", "Stage III Ovarian Epithelial Cancer", "Stage III Ovarian Germ Cell Tumor", "Stage III Prostate Cancer", "Stage III Renal Cell Cancer", "Stage III Uterine Sarcoma", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Neuroendocrine Carcinoma of the Skin", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IV Uterine Sarcoma", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" }, { "name": "vinorelbine ditartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2010-06", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2016-06-13", "last_synced_at": "2026-10-20T01:12:54.931Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01155258" }, { "nct_id": "NCT07510334", "title": "VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-04-21", "completion_date": "2033-08-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-20T01:12:54.931Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07510334" }, { "nct_id": "NCT05103631", "title": "Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Cell Carcinoma", "Solid Tumor", "Wilms Tumor", "Malignant Rhabdoid Tumor", "Yolk Sac Tumor", "Rhabdomyosarcoma", "Liposarcoma", "Embryonal Sarcoma of the Liver" ], "interventions": [ { "name": "CATCH T cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2021-06-17", "completion_date": "2040-12", "has_results": false, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-10-20T01:12:54.931Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05103631" }, { "nct_id": "NCT02526511", "title": "Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage I Renal Cell Cancer", "Stage II Renal Cell Cancer", "Stage III Renal Cell Cancer", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Arterial Spin Labeling Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Perfusion Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2015-04", "completion_date": "2023-09", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-20T01:12:54.931Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02526511" }, { "nct_id": "NCT00101972", "title": "RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "monoclonal antibody RAV12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2004-12", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2022-02-22", "last_synced_at": "2026-10-20T01:12:54.931Z", "location_count": 5, "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101972" }, { "nct_id": "NCT03991130", "title": "High Dose IL-2 in Combination With Anti-PD-1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Renal Cell Carcinoma, Metastatic" ], "interventions": [ { "name": "IL-2 and Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gregory Daniels", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2019-07-17", "completion_date": "2024-08-16", "has_results": true, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-20T01:12:54.931Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03991130" }, { "nct_id": "NCT02782715", "title": "Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" }, { "name": "Microwave Ablation (MWA)", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-06-28", "completion_date": "2023-01-10", "has_results": true, "last_update_posted_date": "2024-03-20", "last_synced_at": "2026-10-20T01:12:54.931Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02782715" } ] }